Regenicin, Inc.
RGIN · OTC
3/31/2023 | 12/31/2022 | 9/30/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.00 | -0.07 | 0.00 |
| FCF Yield | -152.78% | -471.44% | -0.02% | -0.60% |
| EV / EBITDA | 30.69 | 51.93 | -8.88 | -15.14 |
| Quality | ||||
| ROIC | 5.89% | 5.12% | 2.96% | 3.18% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.98 | 1.30 | 0.00 | 0.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 9.26% | -482,289.33% | 99.26% | -54.59% |
| Safety | ||||
| Net Debt / EBITDA | 31.35 | 52.29 | -4.98 | -4.11 |
| Interest Coverage | -35.45 | -28.49 | -15.73 | -17.01 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |